Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the revenue impact of Qelbree, GOCOVRI, and Trokendi XR across multiple neurology markets can bury investors in acronyms and clinical jargon. Supernus Pharmaceuticals’ SEC disclosures often exceed 250 pages and span everything from patent expirations to pivotal trial read-outs—critical data that isn’t easy to spot.
That’s why Stock Titan pairs every Supernus Pharmaceuticals SEC filing with AI-powered summaries that turn technical language into clear takeaways. Need the Supernus Pharmaceuticals annual report 10-K simplified or the latest Supernus Pharmaceuticals quarterly earnings report 10-Q filing? We surface segment sales, pipeline timelines, and royalty assumptions in seconds. Our engine flags Supernus Pharmaceuticals insider trading Form 4 transactions and pushes Supernus Pharmaceuticals Form 4 insider transactions real-time alerts the moment executives trade stock. Even sudden disclosures—see the next Supernus Pharmaceuticals 8-K material events explained—arrive on your dashboard as soon as they hit EDGAR.
Investors often ask, “Where do I find the proxy details on management pay?” One click delivers the Supernus Pharmaceuticals proxy statement executive compensation with plain-English highlights. Curious about financing terms or trial milestones? Our coverage spans every exhibit, note, and risk factor. Here’s what you can do next:
- Compare R&D spend quarter-over-quarter with Supernus Pharmaceuticals earnings report filing analysis.
- Monitor CEO and director moves via Supernus Pharmaceuticals executive stock transactions Form 4.
- Save hours by understanding Supernus Pharmaceuticals SEC documents with AI instead of line-by-line reading.
All forms—10-K, 10-Q, 8-K, S-3s, and more—update in real time, backed by expert commentary that clarifies how each disclosure may affect future CNS drug revenue. Complex biotech filings, explained simply, so you can focus on decisions, not document digging.
Savers Value Village, Inc. (SVV) filed a Form 144 indicating that an insider intends to sell up to 600 common shares through Fidelity Brokerage Services on or after 22 Jul 2025. Based on the reference price in the notice, the stake is valued at $6,306. With 157,451,564 shares outstanding, the proposed sale equals roughly 0.0004 % of the float, implying negligible market impact.
The seller, identified in the three-month sales table as Richard Medway, has already disposed of 36,513 shares between May and July 2025 for gross proceeds of about $402 k. The 600 shares originate from a stock option granted 12 Jun 2019 and exercised for cash on the planned sale date.
This filing is routine compliance with Rule 144 for restricted/control securities. Given the de-minimis size relative to daily volume and market cap, the event is unlikely to influence valuation, though investors may note the ongoing insider selling trend.
FAQ
What is the current stock price of Supernus Pharma (SUPN)?
What is the market cap of Supernus Pharma (SUPN)?
What is the core focus of Supernus Pharmaceuticals?
Which therapeutic areas does Supernus address?
How does Supernus differentiate its product development approach?
What makes Supernus Pharmaceuticals an experienced player in the market?
How does the company ensure the safety and efficacy of its treatments?
What role do partnerships play in Supernus' business model?
How does Supernus approach clinical research?
Why is Supernus considered a trusted source in CNS therapeutics?
